Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Cytokinetics › CEO exercised or converted 7,500 CYTK derivative securities Insider trades
Why it stands out Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Sep 28, 2026
Reporting period Not applicable
Filed with the SEC Sep 28, 2026 CEO Option exercise
Context Classification option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0001061983-26-000097
Filed / recorded
Sep 28, 2026, 8:54 PM UTC
Added to OQRO Oct 6, 2026, 7:14 PM UTC
Data quality Verified: identifiers matched exactly
Reporting person Robert I Blum
Relationship Director, Officer
Officer title President & CEO
Security Non-Qualified Stock Option (Right to Buy)
Table Derivative (Table II)
Transaction date Sep 28, 2026
Acquired / disposed Disposed (D)
Shares owned after 149,245
Around the same time Insider filing
Traded Oct 16 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Oct 16 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Oct 16 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Jul 30, 2026 Insider Officer sold ~$1.12M of CYTK shares in the open market Aug 6, 2026 Company filing · Form 8-K · Results Reported its results Aug 10, 2026 Insider CEO sold ~$576K of CYTK shares in the open market Aug 18, 2026 Insider Officer sold ~$265K of CYTK shares in the open market Aug 31, 2026 Insider · 2 people Insiders: 2 sales (~$1.2M) Sep 1, 2026 Insider Director sold ~$357K of CYTK shares in the open market Sep 8, 2026 Insider Officer sold ~$264K of CYTK shares in the open market Sep 11, 2026 Insider Director sold ~$75K of CYTK shares in the open market Sep 14, 2026 Insider CEO sold ~$551K of CYTK shares in the open market Sep 15, 2026 Insider · 2 people Insiders: 2 sales (~$6.9M) Sep 22, 2026 Insider Officer sold ~$239K of CYTK shares in the open market Sep 28, 2026 Insider CEO sold ~$491K of CYTK shares in the open market What came next Sep 29, 2026 Congress Disclosed purchase of CYTK — reported range $1,001 - $15,000 Oct 6, 2026 Insider Officer sold ~$215K of CYTK shares in the open market Oct 12, 2026 Insider CEO sold ~$472K of CYTK shares in the open market Oct 20, 2026 Insider Officer sold ~$224K of CYTK shares in the open market Nov 2, 2026 Insider CEO sold ~$471K of CYTK shares in the open market